Microvessel density in advanced XXXX before and after chemotherapy.

@entity1 @entity41 @entity5 @entity3003 @entity1311 @entity1503 @entity2280 @entity213
OBJECTIVE: Studies of @entity5 angiogenesis in @entity213 ( @entity213 ) in regard to correlation with prognostic significance have yielded inconclusive results. To determine whether the microvessel density (MVD) within the @entity5 of advanced (Stages III and IV) @entity213 has any impact on @entity5 response to 2-3 courses of @entity1311 ( @entity1311 ) and @entity3003 , we prospectively studied pre-chemotherapy specimens from @entity1 with previously untreated, advanced stage @entity213 . We also attempted to study @entity41 after chemotherapy to determine if the MVD within the @entity5 had changed. STUDY DESIGN: The MVD within the @entity5 was obtained by immunohistochemical staining of the @entity5 with Q-Bend 10 ( @entity2280 ). The "hot-spot" areas of each @entity5 (ie., areas with most intense @entity1503 ) were considered for evaluation. Results were expressed as the Average number of microvessels identified in 5-400x microscope fields (ie., the number of microvessels counted in 5-400x microscope fields divided by 5). SETTING: Tertiary University Medical Center. INTERVENTION: Two to 3 courses of chemotherapy with @entity1311 and @entity3003 . MAIN OUTCOME MEASURES: Progression-free and overall survival with 5 years follow-up, RESULTS: The tumoral MVD in 32 @entity213 specimens before chemotherapy ranged from 4.0-39.0 (mean, 14.8; median, 14.2). Eight out of 32 @entity1 achieved pathologically complete remission; their tumoral MVD revealed a mean of 10.9. The 24 remaining @entity1 had pathologically-confirmed @entity41 post-chemotherapy; their tumoral MVD revealed a mean of 16.5. CONCLUSION: Statistical analyses revealed no evidence of a relationship between remission and a MVD > or < 10 or > or < 16.5. There was no correlation of tumoral MVD with overall or progression-free survival. In 15 @entity1 , tumoral MVD results were also available on the post-chemotherapy specimens. The greater the difference of the tumoral MVD between the pre- and post-chemotherapy specimens, the shorter the @entity1 overall and progression-free survival (p = 0.042).
